(Q37910724)

25 August 2017

1 reference

title

Molecular basis for the actions of Hsp90 inhibitors and cancer therapy (English)

1 reference

25 August 2017

Hiroshi Yamaki

1

1 reference

25 August 2017

Motowo Nakajima

series ordinal

2

1 reference

25 August 2017

Kumiko W Shimotohno

series ordinal

3

1 reference

25 August 2017

Nobuo Tanaka

series ordinal

4

1 reference

25 August 2017

publication date

3 August 2011

1 reference

The Journal of Antibiotics

25 August 2017

published in

1 reference

25 August 2017

volume

64

1 reference

25 August 2017

issue

9

1 reference

25 August 2017

page(s)

635-644

1 reference

The HSP90 family of genes in the human genome: insights into their divergence and evolution

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Heat shock proteins in cancer: chaperones of tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK-independent cell cycle arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

The Hsp90 molecular chaperone: an open and shut case for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Dynamics of heat shock protein 90 C-terminal dimerization is an important part of its conformational cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

The middle domain of Hsp90 acts as a discriminator between different types of client proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

A Nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Novel mechanisms of E2F induction by BK virus large-T antigen: requirement of both the pRb-binding and the J domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Cyclin E, a redundant cyclin in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Amino-terminal domains of c-myc and N-myc proteins mediate binding to the retinoblastoma gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Direct activation of RNA polymerase III transcription by c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Ribo-gnome: the big world of small RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Control of cell proliferation pathways by microRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

let-7 microRNA functions as a potential growth suppressor in human colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Hsp90 regulates the function of argonaute 2 and its recruitment to stress granules and P-bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Unexpected induction of the human connexin 43 promoter by the ras signaling pathway is mediated by a novel putative promoter sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Specific association of a set of molecular chaperones including HSP90 and Cdc37 with MOK, a member of the mitogen-activated protein kinase superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

CK2 controls multiple protein kinases by phosphorylating a kinase-targeting molecular chaperone, Cdc37.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Identification of a cis-element that determines autonomous DNA replication in eukaryotic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Differentially active origins of DNA replication in tumor versus normal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Regulation of DNA methyltransferase 1 by the pRb/E2F1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Angiostatic activity of DNA methyltransferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

The critical role of the PE21 element in oncostatin M-mediated transcriptional repression of the p53 tumor suppressor gene in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

AP4 encodes a c-MYC-inducible repressor of p21

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Synthesis and antitumor activity of novel O-carbamoylmethyloxime derivatives of radicicol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Molecular characterization of macbecin as an Hsp90 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Quercetin-induced ubiquitination and down-regulation of Her-2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Antiproliferative and apoptotic activities of tosylcyclonovobiocic acids as potent heat shock protein 90 inhibitors in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Detection of gastric carcinoma-associated MG7-Ag by serum immuno-PCR assay in a high-risk Chinese population, with implication for screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Possible role for serine/threonine phosphorylation in the regulation of the heteroprotein complex between the hsp90 stress protein and the pp60v-src tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Targeting RAS and PI3K in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Targeting Hsp90: small-molecule inhibitors and their clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Romidepsin for the treatment of cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Synthesis and in vitro anti-HSV-1 activity of a novel Hsp90 inhibitor BJ-B11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

HIV-1 Tat enters T cells using coated pits before translocating from acidified endosomes and eliciting biological responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Heat-shock protein hsp90 governs the activity of pp60v-src kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Regulation of c-Src activity by the expression of wild-type v-Src and its kinase-dead double Y416F-K295N mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

The cellular src gene product regulates junctional cell-to-cell communication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

Inhibition of the association with nuclear matrix of pRB, p70 and p40 proteins along with the specific suppression of c-MYC expression by geldanamycin, an inhibitor of Src tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

7 January 2021

Inhibition of c-myc gene expression in murine lymphoblastoma cells by geldanamycin and herbimycin, antibiotics of benzoquinoid ansamycin group

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

7 January 2021

Inhibition of DNA synthesis in murine tumor cells by geldanamycin, an antibiotic of the benzoquinoid ansamycin group

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

7 January 2021

Translocation of heparanase into nucleus results in cell differentiation

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

7 January 2021

Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

7 January 2021

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

1 reference

https://api.crossref.org/works/10.1038%2FJA.2011.60

7 January 2021

Identifiers

DOI

10.1038/JA.2011.60

1 reference

25 August 2017

1 reference